for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Ocugen Inc

OCGN.O

Latest Trade

7.53USD

Change

-0.08(-1.05%)

Volume

15,139,122

Today's Range

7.52

 - 

8.08

52 Week Range

0.25

 - 

18.77

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
7.61
Open
7.53
Volume
15,139,122
3M AVG Volume
338.64
Today's High
8.08
Today's Low
7.52
52 Week High
18.77
52 Week Low
0.25
Shares Out (MIL)
198.76
Market Cap (MIL)
1,490.67
Forward P/E
-26.79
Dividend (Yield %)
--

Next Event

Ocugen Inc at Cantor Fitzgerald Global Healthcare Conference (Virtual)

Latest Developments

More

Ocugen Provides Business Update And Second Quarter 2021 Financial Results

Ocugen Says Co And Bharat Entered Into That Certain First Amendment To Co-Development, Supply And Commercialization Agreement

Ocugen Expands Covaxin™ Commercialization Rights To Include Canada

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Ocugen Inc

Ocugen, Inc. is a biopharmaceutical company focused on developing gene therapies to cure blindness diseases and developing vaccine for COVID-19. The Company's technology pipeline includes: COVID-19 Vaccine (0.5), Modifier Gene Therapy Platform and Novel Biologic Therapies for Retinal Diseases. COVID-19 Vaccine is developing, manufacturing and commercializing COVAXIN for the prevention of COVID-19 in humans in the Ocugen Covaxin Territory. COVAXIN is a whole-virion inactivated COVID-19 vaccine candidate and is formulated with the inactivated SARS-CoV-2 virus. The Modifier Gene Therapy platform is designed for retinal diseases, including retinitis pigmentosa (RP), leber congenital amaurosis (LCA) and dry age-related macular degeneration (AMD). It is developing OCU200, a novel biologic product candidate to treat diabetic macular edema (DME), diabetic retinopathy (DR) and wet AMD. OCU400, its first product candidate being developed with its modifier gene therapy platform.

Industry

Biotechnology & Drugs

Contact Info

263 GREAT VALLEY PARKWAY

MALVERN, PA

19355

United States

+1.484.3284701

http://www.histogenics.com/

Executive Leadership

Shankar Musunuri

Chairman of the Board, Chief Executive Officer

Sanjay Subramanian

Chief Financial Officer, Company Secretary, Head of Corporate Development

Vijay Tammara

Senior Vice President - Regulatory and Quality

Kirsten Castillo

Independent Director

Prabhavathi B. Fernandes

Independent Director

Key Stats

2.60 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020

0.0K

2021(E)

0.0K
EPS (USD)

2019

-1.260

2020

-0.310

2021(E)

-0.280
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
12.80
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
1.44
LT Debt To Equity (MRQ)
1.44
Return on Investment (TTM)
-69.48
Return on Equity (TTM)
-63.91

Latest News

Latest News

Ocugen says Indian partner's vaccine 93.4% effective against severe COVID-19

The COVID-19 vaccine developed by Ocugen Inc's Indian partner, Bharat Biotech, has been found to be 93.4% effective against severe cases of COVID-19 in a late-stage trial, the U.S. drug developer said on Friday.

Ocugen seeks to sell 100 million Indian vaccine doses in U.S. in 2021

Ocugen Inc seeks to sell 100 million doses of India's state-backed COVID-19 vaccine COVAXIN in the United States this year, the U.S. firm's chief executive Shankar Musunuri told Reuters on Monday.

EXCLUSIVE-Ocugen plans to sell 100 mln Indian vaccine doses in U.S. in 2021

Ocugen Inc plans to sell 100 million doses of India's state-backed COVID-19 vaccine in the United States this year, the U.S. firm's chief executive Shankar Musunuri told Reuters on Monday.

Ocugen to co-develop Bharat Biotech's COVID-19 vaccine candidate for U.S.

Drug developer Ocugen Inc said on Tuesday it had partnered with Bharat Biotech to co-develop the India-based company's COVID-19 vaccine candidate for the U.S. market.

Ocugen to co-develop Bharat Biotech's COVID-19 vaccine candidate for U.S.

Drug developer Ocugen Inc will co-develop India-based Bharat Biotech's COVID-19 vaccine candidate for the U.S. market, the companies said on Tuesday.

BRIEF-Ocugen Says Chief Medical Officer & Chief Scientific Officer Were Notified Of Their Employment Termination

* OCUGEN -CHIEF MEDICAL OFFICER & CHIEF SCIENTIFIC OFFICER WERE NOTIFIED OF THEIR EMPLOYMENT TERMINATION EFFECTIVE JULY 15 & DEC 31,RESPECTIVELY

BRIEF-Ocugen Says Filed A Prospectus Supplement Related To Offering For Up To $6.2 Mln Of Shares

* OCUGEN INC - FILED A PROSPECTUS SUPPLEMENT RELATED TO OFFERING FOR UP TO $6.2 MILLION OF SHARES Source text:(https://bit.ly/2Am98LN) Further company coverage:

BRIEF-Ocugen Inc - Filed A Prospectus Supplement Related To Offering For Up To $6.2 Million Of Shares

* OCUGEN INC - FILED A PROSPECTUS SUPPLEMENT RELATED TO OFFERING FOR UP TO $6.2 MILLION OF SHARES Source text for Eikon: https://bit.ly/37mBUIa Further company coverage:

BRIEF-Ocugen To Discontinue Phase 3 oGVHD Trial

* OCUGEN - DATA MONITORING COMMITTEE INDICATED PHASE 3 OGVHD TRIAL WAS UNLIKELY TO MEET CO-PRIMARY ENDPOINTS UPON COMPLETION

BRIEF-Ocugen Provides Business Update and First Quarter 2020 Financial Results

* REMAIN ON TRACK TO ADVANCE FIRST GENE THERAPY PRODUCT CANDIDATE, OCU400, INTO CLINIC IN 2021

BRIEF-Empery Asset Management Lp Reports 9.99% Passive Stake In Ocugen As Of April 22

* EMPERY ASSET MANAGEMENT LP REPORTS 9.99% PASSIVE STAKE IN OCUGEN AS OF APRIL 22 - SEC FILING Source text - https://bit.ly/3cHGYYY Further company coverage:

BRIEF-Ocugen Says To Postpone 2020 Annual Meeting Of Stockholders Previously Scheduled For Thursday, June 4, 2020

* OCUGEN INC - TO POSTPONE 2020 ANNUAL MEETING OF STOCKHOLDERS PREVIOUSLY SCHEDULED FOR THURSDAY, JUNE 4, 2020 Source: https://bit.ly/2x8BVlq Further company coverage:

BRIEF-Ocugen Files For Mixed Shelf Of Up To $75.0 Million - SEC Filing

* OCUGEN INC FILES FOR MIXED SHELF OF UP TO $75.0 MILLION - SEC FILING Source : (https://bit.ly/3bxLMQc) Further company coverage:

BRIEF-Ocugen Says Over 95% Planned Enrollment Completed In Phase 3 OGVHD Study Topline Results Anticipated By End Of 2020

* OCUGEN- OVER 95% PLANNED ENROLLMENT COMPLETED IN PHASE 3 OGVHD STUDY; TOPLINE RESULTS ANTICIPATED BY END OF 2020

BRIEF-Nature Gene Therapy Publishes Preclinical Data Of Ocugen’S OCU400 Genetic Modifier To Treat Retinitis Pigmentosa

* NATURE GENE THERAPY PUBLISHES PRECLINICAL DATA OF OCUGEN’S OCU400 (NR2E3-AAV) GENETIC MODIFIER TO TREAT RETINITIS PIGMENTOSA (RP)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up